Akoya Biosciences, Inc.

NasdaqGS:AKYA Rapport sur les actions

Capitalisation boursière : US$104.6m

Akoya Biosciences Gestion

Gestion contrôle des critères 3/4

Le PDG Akoya Biosciences est Brian McKelligon, nommé en Jul2017, a un mandat de 7.33 ans. La rémunération annuelle totale est $ 2.92M, composée du salaire de 18.6% et des bonus 81.4%, y compris les actions et options de la société. détient directement 0.075% des actions de la société, d'une valeur de $ 78.56K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 4.3 ans.

Informations clés

Brian McKelligon

Directeur général

US$2.9m

Rémunération totale

Pourcentage du salaire du PDG18.6%
Durée du mandat du directeur général7.3yrs
Propriété du PDG0.08%
Durée moyenne d'occupation des postes de direction2.4yrs
Durée moyenne du mandat des membres du conseil d'administration4.3yrs

Mises à jour récentes de la gestion

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Recent updates

Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Nov 19
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Nov 12
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Analyse de la rémunération des PDG

Comment la rémunération de Brian McKelligon a-t-elle évolué par rapport aux bénéfices de Akoya Biosciences?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$68m

Dec 31 2023US$3mUS$543k

-US$63m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$76m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$3mUS$518k

-US$71m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$2mUS$393k

-US$44m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$516kUS$350k

-US$22m

Dec 31 2019US$484kUS$333k

-US$18m

Rémunération vs marché: La rémunération totale de Brian ($USD 2.92M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 649.07K ).

Rémunération et revenus: La rémunération de Brian a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Brian McKelligon (55 yo)

7.3yrs

Titularisation

US$2,919,599

Compensation

Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 78.6k
John Ek
CFO, Principal Financial Officer & Principal Accounting Officer1.7yrsUS$2.37m0.092%
$ 96.5k
Anthony Catalano
Senior Vice President of Operationsno datapas de donnéespas de données
Priyam Shah
Senior Director of Business Development & Investor Relations Strategyno datapas de donnéespas de données
Jennifer Kamocsay
Chief Legal Officer1.8yrspas de données0.012%
$ 12.9k
Niro Ramachandran
Chief Business Officer4.3yrsUS$365.22k0.29%
$ 305.5k
Pascal Bamford
Senior Vice President of Research & Development and Laboratory Operations3.1yrspas de données0.17%
$ 174.6k
Rob Hart
Secretaryno datapas de donnéespas de données

2.4yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AKYA est considérée comme expérimentée (ancienneté moyenne 2.4 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 78.6k
Robert Shepler
Independent Director9yrsUS$251.66k0.75%
$ 779.8k
Myla Lai-Goldman
Independent Director3.2yrsUS$237.50k0.040%
$ 42.2k
Thomas Schnettler
Independent Director5.2yrsUS$220.00k0%
$ 0
Thomas Raffin
Director9yrsUS$210.00k0.47%
$ 495.0k
Matthew Winkler
Independent Director7.3yrsUS$232.50k1.99%
$ 2.1m
James Allison
Member of Scientific Advisory Boardless than a yearpas de donnéespas de données
Scott Mendel
Independent Chairman3.4yrsUS$250.00k0.058%
$ 60.1k
Padmanee Sharma
Member of Scientific Advisory Boardless than a yearpas de donnéespas de données
Garry Nolan
Chair of the Scientific Advisory Boardless than a yearUS$220.00k1.24%
$ 1.3m

4.3yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AKYA sont considérés comme expérimentés (ancienneté moyenne 4.3 ans).